NCT01866449View on ClinicalTrials.gov

Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

August 25, 2017

Conditions

Glioblastoma Multiforme (GBM) WHO Grade IV

Interventions

DRUG

Cabazitaxel

Trial Locations (3)

56068

Stiftungsklinikum Mittelrhein GmbH, Koblenz

86150

Hämatologisch onkologische Praxis, Augsburg

89081

Lars Bullinger, MD, Ulm

All Listed Sponsors

lead

University of Ulm

OTHER

NCT01866449 - Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter